These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 34663208)

  • 1. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
    Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
    BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease.
    Hirayama H; Morita Y; Imai T; Takahashi K; Yoshida A; Bamba S; Inatomi O; Andoh A
    BMC Gastroenterol; 2022 Apr; 22(1):195. PubMed ID: 35448957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
    Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
    Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
    Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
    Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical remission and transmural healing of ustekinumab in patients with Crohn's disease].
    Wu Y; Xu Y; Zhang G; Zhang Y; Wang J; You P; Peng T; Liu Y; Chen N
    Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):253-259. PubMed ID: 38595241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
    McDonald C; Kerr H; Gibbons E; Lukose T; Cheriyan D; Harewood G; Patchett S; O'Toole A; Kelly O; Boland K
    Inflamm Bowel Dis; 2024 Mar; 30(3):423-428. PubMed ID: 37158577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn's disease.
    Liefferinckx C; Hubert A; Thomas D; Bottieau J; Minsart C; Cremer A; Amininejad L; Vallée F; Toubeau JF; Franchimont D
    Dig Liver Dis; 2023 Mar; 55(3):366-372. PubMed ID: 35977875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis on the efficacy of dual vein induction therapy of Ustekinumab in complex perianal fistulizing Crohn's disease].
    Zhang DL; Shao XX; Hu DY; Lin DP; Wu H; Jiang Y
    Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(41):3301-3306. PubMed ID: 37926575
    [No Abstract]   [Full Text] [Related]  

  • 10. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.
    Painchart C; Brabant S; Duveau N; Nachury M; Desreumaux P; Branche J; Gérard R; Prevost CLD; Wils P; Lambin T; Boualit M; Labalette M; Pariente B
    Dig Dis Sci; 2020 May; 65(5):1445-1452. PubMed ID: 31599389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study.
    Gómez Espín R; Nicolás De Prado I; Gil Candel M; González Carrión M; Rentero Redondo L; Iniesta Navalón C
    Rev Esp Enferm Dig; 2021 Feb; 113(2):110-115. PubMed ID: 33213170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction.
    Proietti E; Pauwels RWM; van der Woude CJ; Doukas M; Oudijk L; Peppelenbosch MP; Grohmann U; Crombag MBS; de Vries AC; Fuhler GM
    Inflamm Bowel Dis; 2023 Jul; 29(7):1038-1046. PubMed ID: 35917118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
    Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
    J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
    Straatmijer T; Biemans VBC; Moes DJAR; Hoentjen F; Ter Heine R; Maljaars PWJ; Theeuwen R; Pierik M; Duijvestein M; van der Meulen-de Jong AE;
    Dig Dis Sci; 2023 Jun; 68(6):2647-2657. PubMed ID: 36920666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring in patients with inflammatory bowel disease on ustekinumab.
    Saleh A; Stading R; Miroballi N; Glassner K; Abraham BP
    J Dig Dis; 2024 Apr; 25(4):214-221. PubMed ID: 38587053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab Promotes Radiological Fistula Healing in Perianal Fistulizing Crohn's Disease: A Retrospective Real-World Analysis.
    Yao J; Zhang H; Su T; Peng X; Zhao J; Liu T; Wang W; Hu P; Zhi M; Zhang M
    J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ustekinumab serum concentrations are associated with clinical outcomes in Crohn's disease - a regional multi-center pilot study.
    Thomann AK; Schulte LA; Globig AM; Hoffmann P; Klag T; Itzel T; Teufel A; Schreiner R; Scheffe N; Ebert MP; Wehkamp J; Gauss A; Hasselblatt P; Klaus J; Reindl W
    Z Gastroenterol; 2020 May; 58(5):439-444. PubMed ID: 32045954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
    Adedokun OJ; Xu Z; Gasink C; Jacobstein D; Szapary P; Johanns J; Gao LL; Davis HM; Hanauer SB; Feagan BG; Ghosh S; Sandborn WJ
    Gastroenterology; 2018 May; 154(6):1660-1671. PubMed ID: 29409871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn's disease.
    Yao J; Peng X; Zhong Y; Su T; Bihi A; Zhao J; Liu T; Wang W; Hu P; Zhang M; Zhi M
    Front Med (Lausanne); 2023; 10():1105981. PubMed ID: 37554510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn's disease treated with ustekinumab.
    Ainora ME; Liguori A; Mignini I; Cintoni M; Galasso L; Laterza L; Lopetuso LR; Garcovich M; Riccardi L; Gasbarrini A; Scaldaferri F; Zocco MA
    Therap Adv Gastroenterol; 2024; 17():17562848241259289. PubMed ID: 38912296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.